1-BOC-3-FMOC-氨基-3-哌啶甲酸 | 368866-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 1-BOC-3-FMOC-氨基-3-哌啶甲酸
• 英文名称: 1-[(tert-butoxy)carbonyl]-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}piperidine-3-carboxylic acid
• 英文别名: 3-(9H-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid
• CAS: 368866-21-1
• 化学式: C₂₆H₃₀N₂O₆
• mdl: MFCD02683125
• 分子量: 466.5
• InChiKey: VXJHDZRKJBBFKW-UHFFFAOYSA-N

物化性质

• 沸点：
  657.8±55.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.423
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-BOC-3-FMOC-氨基-3-哌啶甲酸 以 TBME isopropanol 为溶剂， 以to give 3-amino-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid (Isomer 2)的产率得到1-Boc-3-氨基哌啶-3-羧酸
  参考文献：
  名称：

  Quinazoline Derivatives

  摘要：

  公式（I）的喹唑啉衍生物，其中：R1、R2、R3、R3a、R4、R5、R5aR6、R7、a、m和p如描述中所定义。还声明了含有喹唑啉衍生物的制药组合物，将喹唑啉衍生物用作药物的用途以及制备喹唑啉衍生物的过程。公式（I）的喹唑啉衍生物在治疗高增殖性疾病（如癌症）方面是有用的。

  公开号：

  US20070293490A1

文献信息

• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2005075439A1

  公开（公告）日：2005-08-18

  A quinazoline derivative of the formula (I) wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula (I), are useful in the treatment of hyperproliferative disorders such as a cancer.

  一种式(I)的喹唑啉衍生物，其中：R1、R2、R3、R3a、R4、R5、R5a、R6、R7、a、m和p如描述中所定义。还声明含有该喹唑啉衍生物的药物组合物，以及将该喹唑啉衍生物用作药物和制备该喹唑啉衍生物的方法。式(I)的喹唑啉衍生物在治疗高增殖性疾病如癌症方面具有用途。
• Xanthine derivatives,production and use thereof as medicament
  申请人：——

  公开号：US20040077645A1

  公开（公告）日：2004-04-22

  The present invention relates to substituted xanthines of general formula 1 wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式1的取代黄嘌呤，其中R1至R4如权利要求1所定义，其互变异构体和立体异构体，混合物，前药和盐具有有价值的药理学性质，特别是对酶二肽基肽酶IV（DPP-IV）的抑制作用。
• Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
  申请人：Himmelsbach Frank

  公开号：US20060205711A1

  公开（公告）日：2006-09-14

  The present invention relates to substituted xanthines of general formula wherein R 1 to R 4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

  本发明涉及一般式为的取代黄嘌呤，其中R1至R4如权利要求1所定义的互变异构体和立体异构体，其混合物，以及具有有价值的药理学特性的前药和盐，特别是对酶二肽基肽酶-IV（DPP-IV）的抑制作用。